The striatum doesn't just age—it stops listening. We've spent decades assuming motivation loss with age stems from dopamine decline. But what if it's not the supply? What if it's the receptors? D1 and D2 receptors in the striatum undergo subtle shifts in density and coupling efficiency, altering reward valuation without necessarily reducing dopamine levels. Recent rodent studies hint at D2 receptor downregulation preceding dopamine depletion, yet human data is sparse. We're treating the symptom—boosting dopamine—without diagnosing the cause.

This isn't academic. Reward processing scaffolds meaning, agency, and healthspan. If the aged brain is deaf to dopamine, no supplement will restore drive. We need a decisive experiment: simultaneous PET imaging of D1/D2 receptor availability and in vivo dopamine flux measurements via microdialysis in longitudinal aging cohorts, paired with deep behavioral phenotyping of motivation and reward learning. Integrate this with single-cell transcriptomics from post-mortem tissue to map receptor gene expression changes.

The technology exists. What's missing is funding and cross-disciplinary teams—neuroscientists, gerontologists, computational modelers—to map this striatal sensitivity gradient. We have aging biobanks; we just need to correlate them with receptor imaging. This is a public health imperative. Without understanding the receptor landscape, our interventions are shots in the dark.

Who's ready to build this consortium? Let's fund the human studies now, before we waste another decade on misguided trials. The cost of inaction? A longer life without the spark to live it.